New sleepiness drug ORX142 enters first human tests

NCT ID NCT07082829

Recruiting now Symptom relief Sponsor: Centessa Pharmaceuticals (UK) Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called ORX142 in healthy adults and older adults to see if it is safe and how the body processes it. The study also looks at how food affects the drug and whether it can improve alertness in people who are sleep-deprived. About 208 participants will take either ORX142 or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ORX142 tablets
What this could lead to: If successful, this could lead to a new treatment option for people with excessive daytime sleepiness.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if ORX142 will actually help with sleepiness. The study is small and in healthy volunteers, not patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXCESSIVE DAYTIME SLEEPINESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disorders of Excessive Somnolence hypersomnia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXCESSIVE DAYTIME SLEEPINESS

Contacts and locations

Locations

Site #1
RECRUITING

Lincoln, Nebraska, 68502, United States
Site #2
RECRUITING

Eatontown, New Jersey, 07724, United States
Site #3
RECRUITING

New York, New York, 10019, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.